Patent 10576154 was granted and assigned to Novaliq on March, 2020 by the United States Patent and Trademark Office.
The invention provides novel compositions comprising semifluorinated alkanes and at least one compound sensitive or prone to oxidation. The compositions can be used as medicines that are topically administered to an eye or ophthalmic tissue. The invention further provides kits comprising such compositions.